Function-Preserving Therapy Recognized in the Medical Devices Category for its Use of Irreversible Electroporation (IRE) Technology in Treatment of Prostate…
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD)…
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated…
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapysBLA submission…
NEWTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient…
Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17,…
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS…
Findings suggest a subset of Major Depressive Disorder patients may respond preferentially to vasopressin V1b receptor antagonismMUNICH, Oct. 13, 2025…
Phase 1 trial to investigate novel multi-specific HB2198 to treat B cell-mediated autoimmune disorders by targeting both CD19 and CD20…
Preclinical data support SLS009 as a monotherapy or in combination with venetoclax for the treatment of T-PLL, a rare and…